Milrinone Lactate Injection, Solution
NDC Package 83301-0016-2

11-digit billing NDC: 83301001602
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Milrinone Lactate injection is uSP is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. This formulation utilizes a injection, solution delivery system. Marketed by Mullan Pharmaceutical Inc., this product is identified by NDC 83301-0016 and is authorized under FDA application ANDA216373.

Identification & Billing

NDC Package Code
83301-0016-2
Package Description
10 VIAL in 1 CARTON / 1 mL in 1 VIAL (83301-0016-1)
Product Code
83301-0016
11-Digit Billing Format
83301001602
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Milrinone Lactate
Non-Proprietary Name
Milrinone Lactate
Substance Name
Milrinone Lactate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
MILRINONE LACTATE 1 mg/mL
Pharmacologic Class
Usage Information
Milrinone Lactate Injection, USP is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone lactate should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics.  There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.  

Regulatory & Marketing

Labeler Name
Mullan Pharmaceutical Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216373
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-18-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83301-0016-2 identifies a specific commercial package of 10 vial in 1 carton / 1 ml in 1 vial (83301-0016-1) of Milrinone Lactate, a human prescription drug labeled by Mullan Pharmaceutical Inc.. This injection, solution is formulated for intravenous use and contains milrinone lactate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mullan Pharmaceutical Inc. on September 18, 2023. The current certification is valid through December 31, 2027.

How is this Mullan Pharmaceutical Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83301001602. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
83301-0016-2
11-Digit CMS (5-4-2)
83301-0016-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.